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ABSTRACT 
Tryptophan-aspartic acid (WD) repeat-containing protein 34 (WDR34), one of the WDR 
protein superfamilies with five WD40 domains, inhibits a transforming growth 
factor-beta (TGF-β) activated kinase 1 (TAK1)-associated NF-κB activation pathway. 
Nevertheless, little is known about the roles of WDR34 in cancer. The current study 
sought to elucidate the clinical relevance of WDRsfb34 in oral squamous cell carcinoma 
(OSCC). We found WDR34 down-regulation in OSCCs compared with normal control 
tissues using real-time quantitative reverse transcription-polymerase chain reaction, 
immunoblotting, and immunohistochemistry. Models of overexpression of WDR34 
(oeWDR34) showed depressed cellular growth through cell-cycle arrest at the G1 phase. 
To investigate the inhibitory function of WDR34, we challenged oeWDR34 cells with 
interleukin (IL)-1, a ligand for activation of the TAK1-NF-κB pathway and assessed the 
expression of a target gene of the pathway. oeWDR34 strongly inhibited IL-6 expression, 
which is closely related to tumoral growth, compared with control cells, suggesting that 
WDR34 would be a critical molecule for control of tumoral progression. In addition to 
the in vitro experiments, WDR34 negativity was correlated with tumoral growth of 
OSCCs. Our findings suggested that WDR34 inhibits OSCC progression and might be a 
potential tumor-suppressor molecule in OSCCs. 
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1. Introduction 
Tryptophan-aspartic acid repeat-containing (WDR) proteins are intimately involved 
in a variety of cellular processes, such as signal transduction, cytoskeletal dynamics, 
protein trafficking, nuclear export, and RNA processing. WDR34, a member of the WD 
repeat protein superfamily, consists of five WD40 domains that often act as scaffolds to 
recruit other molecules and form functional complexes or protein-protein interactions. 
WD40 proteins play important roles in many fundamental biologic processes including 
signal transduction, histone modification, DNA damage response, transcription regulation, 
RNA processing, protein degradation, and apoptosis [1]. 
Among the members of the WD repeat protein superfamily, several proteins are 
involved in various diseases, e.g., TLE1 and FBXW7 are well-known tumor suppressors 
and are implicated in several cancers [2,3]. The WDR62 mutation was found in patients 
with microcephaly; WDR45 is associated with neurodegeneration [4]. Yeast two-hybrid 
screening indicated that WDR34 interacts with transforming growth factor-beta (TGF-β) 
activated kinase 1 (TAK1) to inhibit its activity [5]. Therefore, WDR34 acts as a 
TAK1-associated suppressor of the NF-κB activation pathway [6]. 
The current study showed that WDR34 was down-regulated in OSCC cells and 
primary OSCCs and that lower WDR34 expression was correlated closely with growth of 
  
OSCC tumors. We also identified a new mechanism of tumoral growth using the WDR34 
overexpression model. 
 
  
  
2. Materials and methods 
2.1. Statement of ethics 
The ethics committee of Chiba University approved the study protocol (protocol 
number, 680). All subjects provided written informed consent before inclusion in the 
study. 
 
2.2. OSCC cells and clinical OSCC tissue samples 
The RIKEN BioResource Center (Tsukuba, Ibaraki, Japan) and the Japanese 
Collection of Research Bioresources (JCRB) (Ibaraki, Osaka, Japan) provided nine 
OSCC cell lines, HSC-2 (oral floor, RCB1945), HSC-3 (tongue, JCRB0623), HSC-4 
(tongue, RCB1902), Sa3 (gingiva, RCB0980), Ca9-22 (gingiva, RCB1976), Ho-1-N-1 
(buccal mucosa, JCRB0831), Ho-1-u-1 (oral floor, RCB2102), KOSC-2 (oral floor, 
JCRB0126), and SAS (tongue, RCB1974). As previously described, human normal oral 
keratinocytes (HNOKs) served as normal control cells. Surgical samples of OSCC were 
acquired at Chiba University Hospital. The Department of Pathology of Chiba University 
Hospital histopathologically diagnosed each sample according to the TNM classification 
of the International Union against Cancer [7–11].  
 
  
2.3. Quantitative reverse transcription- polymerase chain reaction (qRT-PCR) 
Total RNA was extracted, cDNA was generated, and qRT-PCR was performed 
[12,13]. The primer sequence sets were: WDR34, forward, 5′
-TGATGGCTTCGAGGTGAAC-3’, and reverse, 
5’-GGGTAGCCCAGGGTATACAGA-3’, and probe #84 (Universal ProbeLibrary, 
Roche). 
 
2.4. Immunoblot analysis 
To investigate the WDR34 protein expression levels in OSCC cells and HNOKs, 
protein extraction and immunoblot analysis were performed as described previously 
[14,15]. The antibodies were affinity-purified rabbit anti-WDR34 polyclonal antibody 
(dilute concentration 1:200, Novus Biologicals, Cambridge, UK, NBP1-88805) and 
mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) monoclonal antibody 
(dilute concentration 1:200, Santa Cruz Biotechnology, Dallas, TX, USA, sc-32233). 
 
2.5. Immunohistochemistry (IHC) 
IHC was performed as described previously [13-16]. We used the IHC Profiler 
(https://sourceforge.net/projects/ihcprofiler/, Source Forge) for IHC scoring [20]. The 
  
IHC scores were determined in no fewer than three random microscopic fields of view at 
400× magnification in each section. As described previously, the intensities were 
classified into four levels: 0 (none staining); 1 (weak staining); 2 (moderate staining); and 
3 (strong staining) [21]. We multiplied the cellular numbers in the microscopic fields of 
view and the staining intensities of the cells to reach the WDR34 IHC scores. We 
analyzed the scores from 70 patients with OSCC using receiver operating characteristic 
(ROC) curve analysis to determine the cut-off points of the WDR34 IHC scores for each 
clinical classification. ROC curve analysis was performed using EZR (Easy R) software 
available free from Saitama Medical Center, Jichi Medical University 
(http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmed.html) [22]. Independent 
pathologists from Chiba University Hospital who were blinded to the clinical status 
evaluated the degree of immunostaining. 
 
2.6. Transfection of WDR34 overexpression vector 
Two OSCC cell lines (HSC-2 and KOSC-2) were transfected with WDR34 vector 
designed to overexpress WDR34 human cDNA (oeWDR34 cells) (SC319901, OriGene 
Technologies, Rockville, MD, USA) and non-target vector (mock cells) (TR30012, 
OriGene Technologies) using an electroporator (Neon® Transfection System, Life 
  
Technologies Japan, Tokyo, Japan). After transfection, overexpression of WDR34 was 
confirmed by qRT-PCR and immunoblot analysis as described previously [21,23]. 
 
2.7. Cellular proliferation 
We performed a cellular proliferation assay to determine the effect of WDR34 
overexpression on cellular growth in OSCCs. Cells (oeWDR34 and Mock cells) were 
seeded in six-well plates (1 × 104 viable cells/well). This protocol was described 
previously [24,25]. 
 
2.8. Cell-cycle analysis 
 For synchronization at the G2/M phase, the transfectants were treated with 200 
ng/ml nocodazole (Sigma-Aldrich, St. Louis, MO, USA) for 16 h as reported previously 
[26–28]. After treatment, the oeWDR34 and Mock cells were analyzed using the BD 
Cycletest Plus DNA Reagent Kit (Becton-Dickinson, Franklin Lakes, NJ, USA). 
Cell-cycle analysis was performed using the BD AccuriTM C6 Flow Cytometer 
(Becton-Dickinson) [29–31]. 
 
2.9. IL-1 treatment 
  
The transfectants were treated with IL-1 (Sigma-Aldrich) for 1 h. After treatment, 
total RNA was extracted to undergo qRT-PCR [32]. 
 
2.10. Statistical analysis  
The statistical significance was determined using the Mann-Whitney U-test to 
compare the WDR34 expression levels. P < 0.05 was considered statistically significant. 
The relationships between the WDR34 IHC scores and clinicopathologic parameters were 
analyzed using the Fisher’s exact test and χ2 test. 
 
  
  
3. Results 
3.1. Evaluation of WDR34 expression levels in OSCC-derived cell lines 
To evaluate the status of WDR34 expression levels in the cancer-related genes, we 
conducted qRT-PCR and immunoblot analysis in the nine OSCC cells and HNOKs. 
WDR34 mRNA expression was down-regulated significantly in all OSCC cells compared 
with the HNOKs (Fig. 1A, p<0.05). Fig. 1B shows representative data from the 
immunoblot analysis. The WDR34 protein also decreased in all OSCC cells compared 
with the HNOKs.  
 
3.2. Evaluation of WDR34 expression in primary OSCCs 
We evaluated the WDR34 expression in primary OSCCs using the IHC scoring 
system. Representative IHC data for WDR34 in normal oral tissue and primary OSCC are 
shown in Fig. 1C. Intense WDR34 immunoreactivity was seen in the normal oral tissues; 
the primary OSCCs showed almost negative immunostaining. The IHC scores of WDR34 
in normal oral tissues and primary OSCCs, respectively, ranged from 65.6 to 221.6 
(median, 133.2) and 33.8 to 174.2 (median, 102.5). The scores in the primary OSCCs 
were significantly (p < 0.05) lower than in the normal oral tissues (Fig. 1D). The ROC 
curve analysis showed that the cut-off value was 94.804. Using this cut-off value, we 
  
determined that the IHC scores over 94.804 indicated WDR34 positivity. The 
relationships between the WDR34 expression status and clinicopathological parameters 
of the patients with OSCC are shown in Table 1. The WDR34-negative OSCCs were 
correlated significantly (p < 0.05) with primary tumoral size. 
 
3.3. Establishment of WDR34 overexpressed cells 
Since frequent WDR34 down-regulation was seen often in the nine OSCC cells in 
vitro and in vivo (Fig. 1), the two OSCC cell lines (HSC-2 and KOSC-2) were 
transfected with WDR34 overexpression vector (oeWDR34) and non-targeting vector 
(Mock) to investigate the WDR34 function in OSCC cells. qRT-PCR and immunoblot 
analysis were performed to assess the efficacy of the transfection. The WDR34 mRNA 
expression in the oeWDR4 cells was significantly (p<0.05) higher than in the Mock cells 
(Fig. 2A). Similarly, the WDR34 protein level in the oeWDR34 cells also increased 
compared with the Mock cells (Fig. 2B). We performed a cellular proliferation assay to 
evaluate the effect of WDR34 overexpression on cellular growth and found a significant 
(p < 0.05) decrease in cellular growth in the oeWDR34 cells compared with the Mock 
cells, indicating that overexpression of WDR34 affects cellular growth (Fig. 2C). 
 
  
3.4. Cell-cycle analysis of oeWDR34 cells 
The percentage of oeWDR34 cells at the G1 phase was significantly higher than 
that of the Mock cells (Fig. 3A) (p < 0.05). We also assessed the expression levels of 
p21Cip1, cyclin D1, and CDK2 by immunoblot analysis. As expected, p21Cip1 was 
up-regulated and cyclin D1 and CDK2 were down-regulated significantly (p < 0.05) in 
the oeWDR34 cells (Fig. 3B) [33]. These results indicated that oeWDR34 inhibited 
cellular proliferation by cell-cycle arrest at the G1 phase in OSCC cells. 
 
3.5. Inactivation of the TAK1 pathway by WDR34 
Since WDR34 suppresses the TAK1 pathway [34], we treated the oeWDR34 cells 
with IL-1 and assessed the expression levels of IL-6, a target gene of the IL-1 
receptor-TAK1 pathway. The IL-6 mRNA expression after IL-1 treatment was inhibited 
significantly (p < 0.05) in oeWDR34 cells compared with Mock cells (Fig. 4A). 
 
3.6. Relationships between WDR34 expression and clinical classification in OSCCs 
The relationships between the clinicopathologic features of OSCC cases and their 
WDR34 protein levels using the IHC scoring system are shown in Table 1. Among the 
  
clinical classifications, WDR34-negative patients exhibited significantly (p < 0.05) more 
tumoral progression compared with WDR34-positive patients.  
 
  
  
4. Discussion 
The current study provided the first evidence that WDR34 down-regulation occurs 
in OSCCs and is positively correlated with tumoral growth. Exogenous WDR34 
experiments also showed that WDR34 controlled cellular proliferation by arresting 
cell-cycle progression of the G1 phase. Furthermore, WDR34 blocked the IL-1 
receptor-induced TAK1-NF-κB pathway to inhibit the transcriptional regulation 
associated with cellular proliferation (Fig. 4A, B), suggesting that WDR34 might play an 
important role in tumoral progression in OSCCs. 
Missense mutations of WDR34 are observed in patients with autosomal recessive 
chondrodysplasia [35,36]. The mutation points exist on the sequence of critical domains 
of WDR34, indicating that WDR34 suppression of TAK1 is dysregulated in the patients 
with chondrodysplasia [6,35,37]. Since inactivation of WDR34 function also was 
observed in OSCCs, genetic alteration might be a cause of disruption in WDR34 
transcription. 
TAK1, identified as a member of the MAPK kinase kinase family, is critically 
involved in the activation of NF-κB by not only TGF-β but also proinflammatory 
cytokines such as IL-1 [38–41]. Several members of the Ser/Thr protein phosphatase (PP) 
family negatively regulate TAK1 activity, leading to inactivation of the NF-κB pathway 
  
[38,42]. Similar to the previous data using PPs [43], our findings showed that 
overexpressed WDR34 inactivated the expression of IL-6 [43,44], which increases 
tumoral proliferation in several types of cancers, after treatment with IL-1 by inhibiting 
the TAK1-NF-κB pathway. These results strongly suggested that WDR34 is the specific 
inhibitor of TAK1 activity compared with the PPs. 
Consistent with the previous studies that PP2A mediates TGF-β inhibition and 
induces cell-cycle G1 arrest [38,45], a dominant negative experiment of TAK1 showed 
accelerated p21 expression [46]. Our oeWDR34 cells also exhibited cell-cycle arrest at 
the G1 phase with up-regulation of p21Cip1 (Fig. 3), indicating that WDR34 might be a 
critical molecule in the TAK1-NF-κB pathway and a regulator of its downstream genes. 
In conclusion, the current study explored the molecular function of WDR34 in oral 
cancer. Our data indicated that WDR34 overexpression dramatically inhibited the 
TAK1-NF-κB pathway and that the WDR34 status might directly affect tumoral growth 
in OSCCs. Therefore, WDR34 might be a potential tumor suppressor in OSCCs. 
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Legends 
Fig. 1. Down-regulation of WDR34 in OSCC cells. (A) WDR34 mRNA expression in 
OSCC cells by qRT-PCR. Significant (*p<0.05, Mann-Whitney U-test) down-regulation 
of WDR34 mRNA is seen in nine OSCC cells compared with the HNOKs. The data are 
expressed as the mean ± standard error of the mean from triplicate results. (B) 
Representative immunoblot analysis of WDR34 protein expression. Densitometric 
WDR34 protein data are normalized to the GAPDH protein levels. (C) Representative 
IHC results for WDR34 protein in normal oral tissues and primary OSCCs. Original 
magnification, ×400. Scale bars, 50 μm. (D) The status of WDR34 protein expression in 
primary OSCCs (n=70) and normal counterparts based on the IHC scoring system. The 
WDR34 IHC scores of the OSCCs and normal oral tissues range from 65.6 to 221.6 
(median, 133.2) and 33.8 to 174.2 (median, 102.5)), respectively. WDR34 protein 
expression levels in OSCCs are markedly (*p<0.05, Mann-Whitney U-test) lower than in 
normal oral tissues. 
 
Fig. 2. Establishment of WDR34 overexpressed cells. (A) Expression of WDR34 
mRNA in the oeWDR34 cells (HSC-2 and KOSC-2 derived transfectants). WDR34 
mRNA expression in the oeWDR34 cells is significantly (*p<0.05, Mann-Whitney 
  
U-test) higher than that in the Mock cells. (B) Immunoblot analysis of WDR34 protein 
levels in the oeWDR34 cells. The WDR34 protein levels in the oeWDR34 cells are 
increased markedly compared with the Mock cells. (C) Cellular proliferation assays of 
the oeWDR34 cells. The results are expressed as the mean ± standard error of the mean 
of the values from three assays. The cellular growth of the oeWDR34 cells is inhibited 
significantly (*p<0.05, Mann-Whitney U-test) compared with the Mock cells after 96 h.  
 
Fig. 3. Cell-cycle analysis of the oeWDR34 cells. (A) Flow cytometric analysis shows 
the cell-cycle distribution in the oeWDR34 cells after synchronization at the G2/M 
phase using nocodazole. The percentage of the oeWDR34 cells at the G1 phase is 
increased markedly (*p<0.05, Mann-Whitney U-test) compared with the Mock cells. (B) 
Immunoblot analysis shows up-regulation of p21Cip1 and down-regulation of cyclin D1 
and CDK2 in the oeWDR34 cells compared with the Mock cells. 
 
Fig. 4. Inactivation of the TAK1 pathway in the WDR34 overexpressed cells (A) IL-6 
mRNA expression in the oeWDR34 cells by qRT-PCR. Significant (*p<0.05, 
Mann-Whitney U-test) inhibition of IL-6 mRNA after treatment with IL-1 is seen in the 
oeWDR34 cells compared with the Mock cells. The data are expressed as the mean ± 
  
standard error of the mean from triplicate results. (B) Schematic representation of 
inhibition of the TAK1 pathway by WDR34. Overexpression of WDR34 inhibits TAK1 
activity, leading to down-regulation of the downstream molecules. 
 
  
  
Table 1 
Relationships between WDR34 expression and clinical classification in OSCCs. 
Clinical classification Total 
Immunostaining results 
p value 
No. patients 
WDR34-negative WDR34-positive   
Age at surgery (years) 
  
  ≦60 17 6 11 
0.587* 
  ＞60 53 23 30 
Gender 
  
  Male 41 17 24 
0.9944† 
  Female 29 12 17 
T-primary tumoral size 
  
  T1+T2 39 8 31 
0.001†‡ 
  T3+T4 31 21 10 
N-regional lymph node 
  
  Negative 26 8 18 
0.2122† 
  Positive 44 21 23 
Vascular invasion 
  
  Negative 11 3 8 
0.2892† 
  Positive 59 26 33 
TNM stage 
  
  Ⅰ 13 3 10 
0.4651† 
  Ⅱ 26 8 18 
  Ⅲ 7 4 3 
  Ⅳ 24 14 10 
Histopathological type 
  
  Well 54 22 32 
0.8273†   Moderately 14 5 9 
  Poorly 2 2 0 
*χ2 test. 70 29 41   
†Fisher’s exact test. 
    
‡p<0.05. 
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